Literature DB >> 19452510

The Ron receptor tyrosine kinase is not required for adenoma formation in Apc(Min/+) mice.

Sara E Meyer1, Susan E Waltz, Kathleen H Goss.   

Abstract

The Ron receptor tyrosine kinase is overexpressed in approximately half of all human colon cancers. Increased Ron expression positively correlates with tumor progression, and reduction of Ron levels in human colon adenocarcinoma cells reverses their tumorigenic properties. Nearly all colon tumors demonstrate loss of the adenomatous polyposis coli (APC) tumor suppressor, an early initiating event, subsequently leading to beta-catenin stabilization. To understand the role of Ron in early stage intestinal tumorigenesis, we generated Apc-mutant (Apc(Min/+)) mice with and without Ron signaling. Interestingly, we report here that significantly more Apc(Min/+) Ron-deficient mice developed higher tumor burden than Apc(Min/+) mice with wild-type Ron. Even though baseline levels of intestinal crypt proliferation were increased in the Apc(Min/+) Ron-deficient mice, loss of Ron did not influence tumor size or histological appearance of the Apc(Min/+) adenomas, nor was beta-catenin localization changed compared to Apc(Min/+) mice with Ron. Together, these data suggest that Ron may be important in normal intestinal tissue homeostasis, but that the expression of this receptor is not required for the formation and growth of adenomas in Apc(Min/+) mice.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19452510      PMCID: PMC4102426          DOI: 10.1002/mc.20551

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  62 in total

1.  Qualitative and quantitative relationship between dysplastic aberrant crypt foci and tumorigenesis in the Min/+ mouse colon.

Authors:  J E Paulsen; I L Steffensen; E M Løberg; T Husøy; E Namork; J Alexander
Journal:  Cancer Res       Date:  2001-07-01       Impact factor: 12.701

2.  Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene.

Authors:  N Harada; Y Tamai; T Ishikawa; B Sauer; K Takaku; M Oshima; M M Taketo
Journal:  EMBO J       Date:  1999-11-01       Impact factor: 11.598

3.  Suppression of intestinal polyposis in Apc(Min/+) mice by inhibiting nitric oxide production.

Authors:  B Ahn; H Ohshima
Journal:  Cancer Res       Date:  2001-12-01       Impact factor: 12.701

4.  Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma.

Authors:  V Korinek; N Barker; P J Morin; D van Wichen; R de Weger; K W Kinzler; B Vogelstein; H Clevers
Journal:  Science       Date:  1997-03-21       Impact factor: 47.728

5.  Oncogenic mutants of RON and MET receptor tyrosine kinases cause activation of the beta-catenin pathway.

Authors:  A Danilkovitch-Miagkova; A Miagkov; A Skeel; N Nakaigawa; B Zbar; E J Leonard
Journal:  Mol Cell Biol       Date:  2001-09       Impact factor: 4.272

6.  Ron-mediated cytoplasmic signaling is dispensable for viability but is required to limit inflammatory responses.

Authors:  S E Waltz; L Eaton; K Toney-Earley; K A Hess; B E Peace; J R Ihlendorf; M H Wang; K H Kaestner; S J Degen
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

7.  Telomere dysfunction and evolution of intestinal carcinoma in mice and humans.

Authors:  K L Rudolph; M Millard; M W Bosenberg; R A DePinho
Journal:  Nat Genet       Date:  2001-06       Impact factor: 38.330

8.  Overexpression and activation of the RON receptor tyrosine kinase in a panel of human colorectal carcinoma cell lines.

Authors:  Y Q Chen; Y Q Zhou; D Angeloni; A L Kurtz; X Z Qiang; M H Wang
Journal:  Exp Cell Res       Date:  2000-11-25       Impact factor: 3.905

9.  Identification of the modifier of Min 2 (Mom2) locus, a new mutation that influences Apc-induced intestinal neoplasia.

Authors:  Karen A Silverman; Revati Koratkar; Linda D Siracusa; Arthur M Buchberg
Journal:  Genome Res       Date:  2002-01       Impact factor: 9.043

10.  Immunohistochemical analysis of distribution of RON receptor tyrosine kinase in human digestive organs.

Authors:  T Okino; H Egami; H Ohmachi; E Takai; Y Tamori; A Nakagawa; S Nakano; O Sakamoto; T Suda; M Ogawa
Journal:  Dig Dis Sci       Date:  2001-02       Impact factor: 3.199

View more
  5 in total

1.  Ron receptor overexpression in the murine prostate induces prostate intraepithelial neoplasia.

Authors:  Jerilyn K Gray; Andrew M Paluch; William D Stuart; Susan E Waltz
Journal:  Cancer Lett       Date:  2011-09-24       Impact factor: 8.679

Review 2.  Ron receptor tyrosine kinase signaling as a therapeutic target.

Authors:  Nancy M Benight; Susan E Waltz
Journal:  Expert Opin Ther Targets       Date:  2012-07-26       Impact factor: 6.902

3.  The Ron receptor promotes prostate tumor growth in the TRAMP mouse model.

Authors:  M N Thobe; J K Gray; D Gurusamy; A M Paluch; P K Wagh; P Pathrose; A B Lentsch; S E Waltz
Journal:  Oncogene       Date:  2011-05-30       Impact factor: 9.867

4.  HGFL supports mammary tumorigenesis by enhancing tumor cell intrinsic survival and influencing macrophage and T-cell responses.

Authors:  Nancy M Benight; Purnima K Wagh; Glendon M Zinser; Belinda E Peace; William D Stuart; Juozas Vasiliauskas; Peterson Pathrose; Sandra L Starnes; Susan E Waltz
Journal:  Oncotarget       Date:  2015-07-10

Review 5.  MET and RON receptor tyrosine kinases in colorectal adenocarcinoma: molecular features as drug targets and antibody-drug conjugates for therapy.

Authors:  Hang-Ping Yao; Xiang-Min Tong; Rachel Hudson; Ming-Hai Wang
Journal:  J Exp Clin Cancer Res       Date:  2020-09-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.